See more : Apexigen, Inc. (APGN) Income Statement Analysis – Financial Results
Complete financial analysis of Seer, Inc. (SEER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seer, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TerrAscend Corp. (TER.CN) Income Statement Analysis – Financial Results
- Nissan Motor Co., Ltd. (NSANF) Income Statement Analysis – Financial Results
- Tongda Hong Tai Holdings Limited (2363.HK) Income Statement Analysis – Financial Results
- Mercury NZ Limited (MCY.NZ) Income Statement Analysis – Financial Results
- Amir Marketing and Investments in Agriculture Ltd (AMRK.TA) Income Statement Analysis – Financial Results
Seer, Inc. (SEER)
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.18M | 14.69M | 6.39M | 656.00K | 58.00K | 0.00 |
| Cost of Revenue | 8.16M | 7.94M | 3.21M | 0.00 | 701.00K | 100.00K |
| Gross Profit | 7.03M | 6.74M | 3.19M | 656.00K | -643.00K | -100.00K |
| Gross Profit Ratio | 46.29% | 45.91% | 49.87% | 100.00% | -1,108.62% | 0.00% |
| Research & Development | 53.02M | 45.80M | 29.12M | 18.94M | 12.39M | 3.78M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 15.36M | 4.61M | 2.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 58.95M | 58.53M | 45.76M | 15.36M | 4.61M | 2.98M |
| Other Expenses | 0.00 | -351.00K | -223.00K | -9.00K | -58.00K | 0.00 |
| Operating Expenses | 111.97M | 103.98M | 74.66M | 34.31M | 16.94M | 6.76M |
| Cost & Expenses | 120.12M | 111.92M | 77.87M | 34.31M | 16.94M | 6.76M |
| Interest Income | 17.76M | 4.60M | 326.00K | 883.00K | 850.00K | 451.00K |
| Interest Expense | 0.00 | 327.00K | 22.00K | 9.00K | 5.00K | 0.00 |
| Depreciation & Amortization | 5.58M | 5.90M | 3.56M | 1.61M | 701.00K | 100.00K |
| EBITDA | -97.89M | -93.29M | -68.59M | -31.17M | -15.33M | -6.21M |
| EBITDA Ratio | -644.74% | -633.07% | -1,112.72% | -4,994.82% | -26,434.48% | 0.00% |
| Operating Income | -103.46M | -97.24M | -71.47M | -33.65M | -16.88M | -6.76M |
| Operating Income Ratio | -681.48% | -662.14% | -1,117.81% | -5,129.42% | -29,108.62% | 0.00% |
| Total Other Income/Expenses | 17.19M | 4.27M | 304.00K | 874.00K | 845.00K | 451.00K |
| Income Before Tax | -86.28M | -92.97M | -71.17M | -32.78M | -16.04M | -6.31M |
| Income Before Tax Ratio | -568.28% | -633.07% | -1,113.06% | -4,996.19% | -27,651.72% | 0.00% |
| Income Tax Expense | 0.00 | -4.27M | -2.54M | -1.61M | 5.00K | 451.00K |
| Net Income | -86.28M | -88.70M | -68.63M | -31.17M | -16.04M | -6.31M |
| Net Income Ratio | -568.28% | -604.00% | -1,073.40% | -4,751.37% | -27,660.34% | 0.00% |
| EPS | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| EPS Diluted | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| Weighted Avg Shares Out | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
| Weighted Avg Shares Out (Dil) | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Seer to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
Top 4th-Quarter Buys of Lee Ainslie's Maverick Capital
Seer Announces Closing of Public Offering of Common Stock
Seer Announces Pricing of Upsized Public Offering of Common Stock
Seer Announces Proposed Public Offering of Common Stock
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
Seer to Present at the 39th Annual J.P. Morgan Healthcare Conference
Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More
Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
U.S. IPO Weekly Recap: The IPO Market Is Taught A Thing Or Two In An 8 IPO Week
Source: https://incomestatements.info
Category: Stock Reports